PDSS1 and leukemia: ,62,63 In this study, we reveal a novel application of PARPi-induced synthetic lethality by targeting TPRT associated with reactivated TEs in leukemia driven by PcG LoF mutations (Figure 7), which is associated with very poor prognosis and do not have effective therapies.